Literature DB >> 19691368

Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients.

Reinier M van Hest1, Teun van Gelder, Arnold G Vulto, Leslie M Shaw, Ron A A Mathot.   

Abstract

BACKGROUND AND OBJECTIVES: Renal function and the plasma albumin concentration have been shown to correlate with clearance of total mycophenolic acid (MPA). The hypothesis for the underlying mechanism is that low plasma albumin concentrations and accumulation of the glucuronide metabolite of MPA (MPAG) decrease the binding of MPA to albumin. The subsequent increase in the unbound fraction (f(u)) of MPA (MPA(u)) produces an increase in total MPA (MPA(t)) clearance. This study aimed to develop an empirical population pharmacokinetic model to describe the relationships between renal function and albumin concentration and MPAG, MPA(u) and MPA(t), in order to provide insight into the mechanism by which renal function and plasma albumin affect the disposition of MPA.
METHODS: 774 MPA(t), 479 MPA(u) and 772 total MPAG (MPAG(t)) plasma concentrations were available from 88 renal transplant recipients on days 11 and 140 after transplantation. Data were analysed using non-linear mixed-effects modelling.
RESULTS: Time profiles of MPA(u) and MPAG(t) concentrations were adequately described by two 2-compartment pharmacokinetic models with a link between the central compartments, representing the glucuronidation of MPA(u) to form MPAG. MPA(t) concentrations were modelled using: [MPA(t)] = [MPA(u)] + [MPA(u)] * theta(pb), with [MPA(u)] * theta(pb) representing the bound MPA concentration, where [MPA(t)], [MPA(u)] and theta(pb) represent MPA(t) concentration, MPA(u) concentration and a factor that correlates to the total number of protein binding places, respectively. According to this equation, f(u) = [MPA(u)]/[MPA(t)] = 1/(1 + theta(pb)) * theta(pb), and therefore [MPA(t)], was significantly and independently correlated with creatinine clearance (CL(CR)), the plasma albumin concentration and the MPAG(t) concentration (all p < 0.001). A reduction in CL(CR) from 60 to 25 mL/min correlated with an increase in f(u) from 2.7% to 3.5%, accumulation of MPAG(t) concentrations from 50 to 150 mg/L correlated with an increase in f(u) from 2.8% to 3.7%, and a decrease in plasma albumin concentration from 40 to 30 g/L correlated with an increase in f(u) from 2.6% to 3.5%. No significant correlations were detected between MPA(u) clearance and the plasma albumin concentration or CL(CR).
CONCLUSION: The model shows that low CL(CR), low plasma albumin concentrations and high MPAG concentrations decrease MPA(t) exposure by affecting MPA binding to albumin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19691368     DOI: 10.2165/11312600-000000000-00000

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  35 in total

Review 1.  Immunosuppression: practice and trends.

Authors:  Dixon B Kaufman; Ron Shapiro; Michael R Lucey; Wida S Cherikh; Rami T Bustami; David B Dyke
Journal:  Am J Transplant       Date:  2004       Impact factor: 8.086

2.  Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1983-06

3.  The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Authors:  M O Karlsson; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

4.  Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid.

Authors:  T van Gelder; J Klupp; M J Barten; U Christians; R E Morris
Journal:  Ther Drug Monit       Date:  2001-04       Impact factor: 3.681

5.  Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes.

Authors:  M Shipkova; C P Strassburg; F Braun; F Streit; H J Gröne; V W Armstrong; R H Tukey; M Oellerich; E Wieland
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

6.  Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.

Authors:  L T Weber; T Lamersdorf; M Shipkova; P D Niedmann; M Wiesel; L B Zimmerhackl; A Staskewitz; E Schütz; O Mehls; M Oellerich; V W Armstrong; B Tönshoff
Journal:  Ther Drug Monit       Date:  1999-10       Impact factor: 3.681

7.  Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant.

Authors:  Bronwyn A Atcheson; Paul J Taylor; David W Mudge; David W Johnson; Carmel M Hawley; Scott B Campbell; Nicole M Isbel; Peter I Pillans; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of mycophenolate mofetil.

Authors:  R E Bullingham; A J Nicholls; B R Kamm
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

9.  Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics.

Authors:  I Nowak; L M Shaw
Journal:  Clin Chem       Date:  1995-07       Impact factor: 8.327

10.  Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia.

Authors:  Bronwyn A Atcheson; Paul J Taylor; Carl M J Kirkpatrick; Stephen B Duffull; David W Mudge; Peter I Pillans; David W Johnson; Susan E Tett
Journal:  Ther Drug Monit       Date:  2004-06       Impact factor: 3.681

View more
  10 in total

Review 1.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

Authors:  Jeannine S McCune; Meagan J Bemer; Janel Long-Boyle
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

Review 2.  [Dosage and toxicity of antirheumatic drugs in renal insufficiency].

Authors:  S M Weiner; R Bergner
Journal:  Z Rheumatol       Date:  2015-05       Impact factor: 1.372

3.  Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors.

Authors:  Adam Frymoyer; Davide Verotta; Pamala Jacobson; Janel Long-Boyle
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 4.  How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

5.  Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.

Authors:  Brenda C M de Winter; Teun van Gelder; Ferdi Sombogaard; Leslie M Shaw; Reinier M van Hest; Ron A A Mathot
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-11       Impact factor: 2.745

6.  Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach.

Authors:  Helena Colom; Franc Andreu; Teun van Gelder; Dennis A Hesselink; Brenda C M de Winter; Oriol Bestard; Joan Torras; Josep M Cruzado; Josep M Grinyó; Núria Lloberas
Journal:  Clin Pharmacokinet       Date:  2018-07       Impact factor: 6.447

7.  Pharmacokinetics of mycophenolic acid and its phenyl glucuronide metabolite in kidney transplant recipients with renal impairment.

Authors:  Jolanta Kamińska; Maciej Głyda; Joanna Sobiak; Maria Chrzanowska
Journal:  Arch Med Sci       Date:  2012-02-29       Impact factor: 3.318

8.  High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation.

Authors:  Olesja Rissling; Marcel Naik; Susanne Brakemeier; Danilo Schmidt; Oliver Staeck; Arnim Hohberger; Hans-Hellmut Neumayer; Klemens Budde
Journal:  Clin Kidney J       Date:  2018-01-12

9.  Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients.

Authors:  Changcheng Sheng; Qun Zhao; Wanjie Niu; Xiaoyan Qiu; Ming Zhang; Zheng Jiao
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

10.  Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study.

Authors:  François Riglet; Julie Bertrand; Aurélie Barrail-Tran; Céline Verstuyft; Hugues Michelon; Henri Benech; Antoine Durrbach; Valérie Furlan; Caroline Barau
Journal:  Drugs R D       Date:  2020-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.